First patient receives cell-rejuvenation therapy for the optic nerve
Life Biosciences has become the first in the world to dose a patient with a gene therapy that rejuvenates aging cells in the optic nerve, the first human test of partial cellular reprogramming.
US company Life Biosciences has become the first in the world to treat a patient with a gene therapy that aims to rejuvenate aging cells in the optic nerve. It is the first time partial cellular reprogramming, until now mostly studied in mice, has been tested in a human. For the longevity field, that is a milestone.
On 9 June 2026, Life Biosciences announced that the first participant had been dosed in a Phase 1 study of ER-100, an experimental therapy for optic neuropathies. It targets patients with open-angle glaucoma and NAION, a form of acute damage to the optic nerve. The trial primarily tests safety and tolerability, and also looks at effects on visual function. More in the Nature report.
What is ER-100?
ER-100 is a gene therapy that uses a harmless virus (AAV2) to deliver genetic instructions into the cells of the optic nerve. Those instructions produce three so-called Yamanaka factors, OCT4, SOX2 and KLF4, together abbreviated OSK. These proteins reset a cell’s epigenetic “program” to a younger state, without fully turning the cell back into a stem cell. This principle is called partial reprogramming.
To keep the process controllable, its activity can be switched on and off with the drug doxycycline. This lets doctors dose the reprogramming and stop it when needed, a built-in safety brake against uncontrolled cell division.
Why the eye?
The eye is a logical first testing ground: it is easily accessible, relatively sealed off from the rest of the body, and effects on vision are measurable. The goal is to regenerate aging nerve cells in the optic nerve in people slowly losing their sight to glaucoma, a leading cause of blindness worldwide.
How significant is this?
This is an early stage. A Phase 1 study is small and mainly about safety; whether the therapy actually improves vision remains to be seen. Still, the step is symbolically large: partial reprogramming was long studied mostly in mice, and this is the first sign that it is considered safe enough to try in humans.
LongevityWatch previously covered the approval of this trial. Dosing the first patient is the next step in a story we are following closely.